Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

NCT01763164

Last updated date
Study Location
Highlands Oncology Group SC
Fayetteville, Arkansas, 72703, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Metastatic or Unresectable Cutaneous Melanoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of locally advanced, unresectable or metastatic cutaneous or melanoma of unknown primary AJCC Stage IIIC or IV (uveal and mucosal melanoma are excluded)

- Presence of NRAS Q61 mutation in tumor tissue prior to randomization as determined by a Novartis designated central laboratory

- Naïve untreated patients or patients who have progressed on or after any number of prior lines of immunotherapy for unresectable locally advanced or metastatic melanoma

- Evidence of at least one measurable lesion as detected by radiological or photographic methods

- Adequate bone marrow, organ function, cardiac and laboratory parameters

- Normal functioning of daily living activities

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Any untreated CNS metastases


- Uveal or mucosal melanoma


- History of or current evidence of retinal vein occlusion (RVO) or risk factors of RVO


- Patients with washout period < 6 weeks from the last dose of ipilimumab or other
immunotherapy.


- Previous systemic chemotherapy for unresectable locally advanced or metastatic
melanoma.


- History of Gilbert's syndrome


- Prior therapy with a MEK- inhibitor


- Impaired cardiovascular function or clinically significant cardiovascular diseases


- Uncontrolled arterial hypertension despite medical treatment


- HIV positive or active Hepatitis A or B


- Impairment of gastrointestinal function


- Patients who have undergone major surgery or radiotherapy ≤ 3 weeks prior to starting
study drug or who have not recovered from side effects of such procedure;


- Patients with neuromuscular disorders that are associated with elevated CK.


- Pregnant or nursing (lactating) women


- Medical, psychiatric, cognitive or other conditions that may compromise the patient's
ability to understand the patient information, give informed consent, comply with the
study protocol or complete the study


Other protocol-defined inclusion/exclusion criteria may apply

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Metastatic or Unresectable Cutaneous MelanomaStudy Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
NCT01763164
  1. Fayetteville, Arkansas
  2. Fort Myers, Florida
  3. Fort Myers, Florida
  4. Park Ridge, Illinois
  5. Goshen, Indiana
  6. Bangor, Maine
  7. Baltimore, Maryland
  8. Boston, Massachusetts
  9. Detroit, Michigan
  10. Minneapolis, Minnesota
  11. Omaha, Nebraska
  12. Camden, New Jersey
  13. Hackensack, New Jersey
  14. Columbus, Ohio
  15. Portland, Oregon
  16. Portland, Oregon
  17. Portland, Oregon
  18. Bethlehem, Pennsylvania
  19. Hershey, Pennsylvania
  20. Philadelphia, Pennsylvania
  21. Nashville, Tennessee
  22. Austin, Texas
  23. Dallas, Texas
  24. Dallas, Texas
  25. Rosario, Santa Fe
  26. Rio Negro, Viedma
  27. Buenos Aires,
  28. Buenos Aires,
  29. Camperdown, New South Wales
  30. Gateshead, New South Wales
  31. North Sydney, New South Wales
  32. Woolloongabba, Queensland
  33. Adelaide, South Australia
  34. Innsbruck, Tyrol
  35. Graz,
  36. Salzburg,
  37. Wien,
  38. Leuven,
  39. Liege,
  40. Wilrijk,
  41. Rio de Janeiro, RJ
  42. Passo Fundo, RS
  43. Porto Alegre, RS
  44. Sao Paulo, SP
  45. Edmonton, Alberta
  46. London, Ontario
  47. Toronto, Ontario
  48. Toronto, Ontario
  49. Montreal, Quebec
  50. Sainte-Foy, Quebec
  51. Ostrava Poruba, Czech Republic
  52. Brno,
  53. Praha 10,
  54. Praha 2,
  55. Paris, Cedex 10
  56. Angers,
  57. Bordeaux Cedex,
  58. Boulogne Billancourt,
  59. Le Mans Cedex 09,
  60. LILLE Cedex,
  61. Lyon Cedex,
  62. Marseille Cedex 05,
  63. Nice Cedex 3,
  64. Pierre-Benite Cedex,
  65. Reims,
  66. Rouen Cedex,
  67. Mannheim, Baden-Württemberg
  68. Berlin,
  69. Dresden,
  70. Erfurt,
  71. Essen,
  72. Frankfurt,
  73. Freiburg,
  74. Gera,
  75. Hannover,
  76. Heidelberg,
  77. Kiel,
  78. Köln,
  79. Leipzig,
  80. Lübeck,
  81. Minden,
  82. Muenchen,
  83. Muenster,
  84. Nuernberg,
  85. Quedlinburg,
  86. Regensburg,
  87. Stade,
  88. Tübingen,
  89. Ulm,
  90. Würzburg,
  91. Athens, GR
  92. Budapest,
  93. Budapest,
  94. Kaposvar,
  95. Szolnok,
  96. Haifa,
  97. Jerusalem,
  98. Ramat Gan,
  99. Bari, BA
  100. Bergamo, BG
  101. Brescia, BS
  102. Genova, GE
  103. Milano, MI
  104. Padova, PD
  105. Roma, RM
  106. Roma, RM
  107. Siena, SI
  108. Torino, TO
  109. Napoli,
  110. Fukuoka-city, Fukuoka
  111. Matsumoto, Nagano
  112. Hirakata-city, Osaka
  113. Chuo-ku, Tokyo
  114. Seoul, Korea
  115. Seoul, Korea
  116. Seoul, Korea
  117. Seoul, Korea
  118. Amsterdam,
  119. Leiden,
  120. Nijmegen,
  121. Zwolle,
  122. Warszawa,
  123. Almada,
  124. Lisboa,
  125. Lisboa,
  126. Porto,
  127. Moscow,
  128. Ryazan,
  129. St. Petersburg,
  130. Bratislava, Slovak Republic
  131. Bloemfontein,
  132. Johannesburg,
  133. Pretoria,
  134. Pretoria,
  135. Malaga, Andalucia
  136. Sevilla, Andalucia
  137. Toledo, Castilla La Mancha
  138. Barcelona, Catalunya
  139. Barcelona, Catalunya
  140. Hospitalet de LLobregat, Catalunya
  141. Valencia, Comunidad Valenciana
  142. Valencia, Comunidad Valenciana
  143. Badajoz, Extremadura
  144. La Coruna, Galicia
  145. Las Palmas De Gran Canarias, Las Palmas De Gran Canaria
  146. Pamplona, Navarra
  147. Madrid,
  148. Madrid,
  149. Madrid,
  150. Madrid,
  151. Lund,
  152. Genève,
  153. Lausanne,
  154. Zürich,
  155. Ankara,
  156. Istanbul,
  157. Izmir,
  158. Bristol, Avon
  159. Truro, Cornwall
  160. Surrey, England
  161. Birmingham, Surrey
  162. Leeds, West Yorkshire
  163. Chelmsford,
  164. London,
  165. Merseyside,
  166. Preston,
  167. Swansea,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Official Title  ICMJE A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Brief Summary Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC) unresectable or metastatic (Stage IV) NRAS Q61 mutation-positive cutaneous or unknown primary melanoma. The mutation analysis will be performed at a central laboratory. Only those patients with Q61 mutation per central laboratory and meet all eligibility criteria will be randomized. A total of 393 patients will be randomized 2:1 to receive either MEK162 or dacarbazine. Patients will be stratified according to AJCC stage (IIIC, IVM1a, and IVM1b versus IVM1c), ECOG Performance status (0 versus 1) and any prior number of lines of immunotherapy (immunotherapies versus none). This study will use an Interactive Response Technology (IRT). The primary end point of the study is progression-free survival. Key secondary end point is overall survival
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Metastatic or Unresectable Cutaneous Melanoma
Intervention  ICMJE
  • Drug: MEK162
    MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
  • Drug: Dacarbazine
    Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.
Study Arms  ICMJE
  • Experimental: MEK162
    Intervention: Drug: MEK162
  • Active Comparator: Dacarbazine
    Intervention: Drug: Dacarbazine
Publications * Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Apr;18(4):435-445. doi: 10.1016/S1470-2045(17)30180-8. Epub 2017 Mar 9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 13, 2016)
402
Original Estimated Enrollment  ICMJE
 (submitted: January 4, 2013)
393
Actual Study Completion Date  ICMJE June 4, 2019
Actual Primary Completion Date December 1, 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of locally advanced, unresectable or metastatic cutaneous or melanoma of unknown primary AJCC Stage IIIC or IV (uveal and mucosal melanoma are excluded)
  • Presence of NRAS Q61 mutation in tumor tissue prior to randomization as determined by a Novartis designated central laboratory
  • Naïve untreated patients or patients who have progressed on or after any number of prior lines of immunotherapy for unresectable locally advanced or metastatic melanoma
  • Evidence of at least one measurable lesion as detected by radiological or photographic methods
  • Adequate bone marrow, organ function, cardiac and laboratory parameters
  • Normal functioning of daily living activities

Exclusion Criteria:

  • Any untreated CNS metastases
  • Uveal or mucosal melanoma
  • History of or current evidence of retinal vein occlusion (RVO) or risk factors of RVO
  • Patients with washout period < 6 weeks from the last dose of ipilimumab or other immunotherapy.
  • Previous systemic chemotherapy for unresectable locally advanced or metastatic melanoma.
  • History of Gilbert's syndrome
  • Prior therapy with a MEK- inhibitor
  • Impaired cardiovascular function or clinically significant cardiovascular diseases
  • Uncontrolled arterial hypertension despite medical treatment
  • HIV positive or active Hepatitis A or B
  • Impairment of gastrointestinal function
  • Patients who have undergone major surgery or radiotherapy ? 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure;
  • Patients with neuromuscular disorders that are associated with elevated CK.
  • Pregnant or nursing (lactating) women
  • Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study

Other protocol-defined inclusion/exclusion criteria may apply

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Austria,   Belgium,   Brazil,   Canada,   Czechia,   France,   Germany,   Greece,   Hungary,   Israel,   Italy,   Japan,   Korea, Republic of,   Netherlands,   Poland,   Portugal,   Russian Federation,   Slovakia,   South Africa,   Spain,   Sweden,   Switzerland,   Turkey,   United Kingdom,   United States
Removed Location Countries Czech Republic
 
Administrative Information
NCT Number  ICMJE NCT01763164
Other Study ID Numbers  ICMJE CMEK162A2301
2012-003593-51 ( EudraCT Number )
C4211002 ( Other Identifier: Pfizer )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:PfizerCT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP